Prostacyclin receptor agonist

DRUG2 trials

Sponsors

Actelion, Academisch Medisch Centrum

Conditions

Pulmonary Arterial Hypertensionhypertension in the pulmonary arteries Pulmonary arterial hypertension due to congenital heart disease

Phase 1

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

CompletedNCT05427162

ActelionPulmonary Arterial Hypertension

Start: 2022-06-21End: 2023-12-05Updated: 2025-03-30

Phase 3

Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease

Academisch Medisch Centrumhypertension in the pulmonary arteries Pulmonary arterial hypertension due to congenital heart disease

Target: 60Updated: 2024-02-28